NewAmsterdam Pharma Company (NAMS) Income Statement: Revenue & Earnings

NewAmsterdam Pharma Company Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

NewAmsterdam Pharma Company N.V. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	45.56	14.09	102.69	0.00	0.00
Cost of Revenue	0.00	27.43	0.00	0.00	0.00
Gross Profit	45.56	14.09	102.69	0.00	0.00
Operating Expenses
Research & Development	151.41	159.42	86.74	28.97	4.95
Selling, General & Administrative	70.45	37.63	19.51	6.00	1.69
Operating Expenses	221.85	197.06	106.25	34.98	6.64
Operating Income	-176.29	-182.97	-3.56	-34.98	-6.64
Other Income/Expense
Interest Income	16.88	11.28	0.00	0.00	0.00
Interest Expense	0.00	0.00	-0.29	-0.41	-0.42
Other Income/Expense	-65.31	-5.23	-8.34	-7.22	0.00
Income
Income Before Tax	-241.60	-176.91	-22.63	-41.79	-7.03
Income Tax Expense	0.00	0.03	0.00	0.00	0.00
Net Income	-241.60	-176.94	-22.63	-41.79	-7.03
Net Income - Continuous Operations	-241.60	-176.94	-22.63	-41.79	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-241.49	-176.86	-3.55	-34.97	-6.64
EBIT	-241.60	-176.91	-3.56	-34.98	-6.64
Depreciation & Amortization	0.11	0.05	0.01	0.01	0.00
Earnings Per Share
Basic EPS	-3.00	-2.00	-1.00	-4.00	-1.00
Diluted EPS	-3.00	-2.00	-1.00	-4.00	-1.00
Basic Shares Outstanding	94.36	82.16	18.97	10.98	5.00
Diluted Shares Outstanding	94.36	82.16	18.97	10.98	5.00